Is PARAESTHESIA a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed PARAESTHESIA.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 49 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported PARAESTHESIA to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and PARAESTHESIA. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause PARAESTHESIA, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes PARAESTHESIA. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if PARAESTHESIA ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing PARAESTHESIA: 49
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where PARAESTHESIA is a reported side effect: 1.4719%

FDA reports of any drug causing PARAESTHESIA : 45962
Average percentage for all medicated patients where PARAESTHESIA is reported as a complication: 0.2881%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with PARAESTHESIA:

ASPIRIN (4987 patients)
NIASPAN (4385 patients)
FOSAMAX (3034 patients)
HUMIRA (2414 patients)
PAXIL (2107 patients)
VIOXX (2053 patients)
LIPITOR (2010 patients)
ENBREL (1989 patients)
ZOMETA (1830 patients)
CYMBALTA (1807 patients)
LYRICA (1715 patients)
TYSABRI (1708 patients)
LISINOPRIL (1659 patients)
REMICADE (1557 patients)
NEURONTIN (1549 patients)
PREDNISONE (1512 patients)
AVONEX (1494 patients)
SIMCOR (1490 patients)
SYNTHROID (1467 patients)
NEXIUM (1440 patients)
XANAX (1237 patients)
EFFEXOR XR (1210 patients)
METHOTREXATE (1176 patients)
SIMVASTATIN (1174 patients)
ATENOLOL (1174 patients)
OMEPRAZOLE (1173 patients)
ZOLOFT (1124 patients)
LEVAQUIN (1104 patients)
AREDIA (1087 patients)
FOLIC ACID (1073 patients)
SEROQUEL (1070 patients)
PLAVIX (1067 patients)
HYDROCHLOROTHIAZIDE (1034 patients)
AMBIEN (1028 patients)
LASIX (1023 patients)
CRESTOR (1014 patients)
COUMADIN (1002 patients)
VITAMIN D (965 patients)
IBUPROFEN (956 patients)
CELEBREX (945 patients)
FUROSEMIDE (936 patients)
LEXAPRO (922 patients)
PRILOSEC (912 patients)
ZOCOR (907 patients)
GABAPENTIN (903 patients)
EFFEXOR (881 patients)
HEPARIN SODIUM INJECTION (869 patients)
TOPROL-XL (843 patients)
FISH OIL (840 patients)
PROTONIX (839 patients)
DEXAMETHASONE (834 patients)
LEVOTHYROXINE SODIUM (821 patients)
CALCIUM (813 patients)
VICODIN (809 patients)
OXYCONTIN (804 patients)
LORAZEPAM (778 patients)
ALBUTEROL (763 patients)
ATIVAN (721 patients)
ACETAMINOPHEN (714 patients)
AVELOX (696 patients)
FORTEO (692 patients)
PAROXETINE HCL (686 patients)
PREVACID (686 patients)
METFORMIN HCL (684 patients)
NORVASC (679 patients)
TOPAMAX (666 patients)
DIGOXIN (652 patients)
DIAZEPAM (645 patients)
PERCOCET (639 patients)
CLONAZEPAM (632 patients)
MAGNEVIST (627 patients)
SINGULAIR (625 patients)
METOPROLOL TARTRATE (617 patients)
MULTI-VITAMIN (617 patients)
REBIF (616 patients)
PROZAC (616 patients)
DIOVAN (607 patients)
MULTI-VITAMINS (592 patients)
CHANTIX (588 patients)
OXYCODONE HCL (588 patients)
DECADRON (581 patients)
ALLOPURINOL (580 patients)
AMOXICILLIN (567 patients)
PREDNISONE TAB (561 patients)
POTASSIUM CHLORIDE (559 patients)
WELLBUTRIN (558 patients)
BENADRYL (558 patients)
KLONOPIN (557 patients)
CELEXA (538 patients)
PREMARIN (530 patients)
WARFARIN SODIUM (525 patients)
COREG (522 patients)
ADVAIR DISKUS 100/50 (522 patients)
AMLODIPINE (515 patients)
REVLIMID (505 patients)
ALPRAZOLAM (504 patients)
ZOFRAN (503 patients)
FLEXERIL (488 patients)
ZYRTEC (484 patients)
CIPROFLOXACIN (478 patients)
LORTAB (459 patients)
ARIMIDEX (456 patients)
ALLEGRA (453 patients)
TRAZODONE HCL (452 patients)
THALIDOMIDE (443 patients)
LANTUS (440 patients)
LANSOPRAZOLE (436 patients)
VALIUM (429 patients)
VITAMIN B-12 (429 patients)
TRAMADOL HCL (428 patients)
AMITRIPTYLINE HCL (427 patients)
CITALOPRAM HYDROBROMIDE (425 patients)
MORPHINE (419 patients)
VITAMIN E (417 patients)
VELCADE (414 patients)
ZETIA (410 patients)
BETASERON (403 patients)
PRISTIQ (403 patients)
XELODA (400 patients)
DURAGESIC-100 (393 patients)
TAXOTERE (393 patients)
ZANTAC (385 patients)
METOPROLOL (383 patients)
INSULIN (376 patients)
RANITIDINE (374 patients)
CEPHALEXIN (373 patients)
ZITHROMAX (364 patients)
METFORMIN (362 patients)
SPIRIVA (360 patients)
PREDNISOLONE (358 patients)
LAMICTAL (358 patients)
BYETTA (357 patients)
MORPHINE SULFATE (354 patients)
COMPAZINE (349 patients)
BACLOFEN (349 patients)
COZAAR (348 patients)
ZYPREXA (345 patients)
ARANESP (345 patients)
YASMIN (344 patients)
NAPROXEN (342 patients)
ASCORBIC ACID (342 patients)
ACETYLSALICYLIC ACID SRT (340 patients)
ALENDRONATE SODIUM (339 patients)
ACTONEL (336 patients)
CARBOPLATIN (335 patients)
CALCIUM CARBONATE (334 patients)
TAXOL (334 patients)
MIRTAZAPINE (329 patients)
CYCLOPHOSPHAMIDE (328 patients)
RAMIPRIL (327 patients)
GILENYA (327 patients)
TAMOXIFEN CITRATE (322 patients)
NITROGLYCERIN (321 patients)
LOVAZA (320 patients)
ELAVIL (314 patients)
HYDROCODONE (314 patients)
CHEMOTHERAPEUTICS NOS (313 patients)
CLINDAMYCIN (310 patients)
FENTANYL (310 patients)
REGLAN (309 patients)
CIPRO (309 patients)
RADIATION THERAPY (308 patients)
FLOMAX (308 patients)
VYTORIN (308 patients)
SANDOSTATIN LAR (308 patients)
HYDROCODONE BITARTRATE (307 patients)
LEVOXYL (307 patients)
MOTRIN (304 patients)
CLONIDINE (304 patients)
PANTOPRAZOLE (303 patients)
FLONASE (303 patients)
TYLENOL (302 patients)
IRON (301 patients)
PAXIL CR (300 patients)
EPOGEN (300 patients)
FLUOROURACIL (299 patients)
COLACE (298 patients)
TEMAZEPAM (295 patients)
FEMARA (295 patients)
YAZ (291 patients)
ULTRAM (288 patients)
ACTOS (288 patients)
CARVEDILOL (288 patients)
LOVENOX (287 patients)
PRAVASTATIN (287 patients)
GLUCOPHAGE (285 patients)
FERROUS SULFATE TAB (283 patients)
IMITREX (283 patients)
TRICOR (282 patients)
AVANDIA (280 patients)
XOLAIR (278 patients)
VALTREX (272 patients)
PROCRIT /00909301/ (272 patients)
CLARITIN (272 patients)
PROMETHAZINE (271 patients)
FOSAMAX PLUS D (271 patients)
SPIRONOLACTONE (269 patients)
NEXAVAR (268 patients)
THALOMID (266 patients)
LOTREL (266 patients)
VOLTAREN (266 patients)
DILAUDID (265 patients)
TYLENOL (CAPLET) (264 patients)
ACIPHEX (264 patients)
ACYCLOVIR (264 patients)
NUVARING (262 patients)
DOXYCYCLINE (262 patients)
METOCLOPRAMIDE (261 patients)
FLUOXETINE (261 patients)
MIRENA (260 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about PARAESTHESIA and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.